Clinical aspects;Les aspects cliniques

Presse Medicale

Volumn 27, Issue 13, 1998, Pages 628-632

  Modigliani, E ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; DISEASE ASSOCIATION; ENDOCRINE TUMOR; HUMAN; HYPERPARATHYROIDISM; MULTIPLE ENDOCRINE NEOPLASIA; PHEOCHROMOCYTOMA; REVIEW; THYROID CARCINOMA; THYROID HYPERPLASIA; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; GANGLIONEUROMA; GENETICS; HYPERTHYROIDISM; MALE; SEX DIFFERENCE; THYROID TUMOR;

DIAGNOSIS, DIFFERENTIAL; ENDOCRINE GLAND NEOPLASMS; GANGLIONEUROMA; HUMANS; HYPERPARATHYROIDISM; HYPERTHYROIDISM; MALE; PHEOCHROMOCYTOMA; SEX FACTORS; THYROID NEOPLASMS;

EID: 0032481730     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 1961 ; 31:163-6.
2. Modigliani E et le GETC. Le cancer médullaire en France en 1995. Ann Endocrinol 1996 ; 57:3-8.
3. Gorlin RJ, Sedano HO, Vickers RA, Cervenja J. Multiple mucosal neuromas, pheochromocytoma and medullary carcinoma of the thyroid; a syndroma. Cancer 1968 ; 22:293-6.
4. Farndon JR, Leight GS, Dilley WG et al. Familial medullary thyroid carcinoma without associated endocrinopathies : a new clinical entity. Br J Surg 1986 ; 73:278-81.
5. Pacini F, Fontaneili M, Fugazzola L et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroïd carcinoma. J Clin Endocrinol Metab 1994 ; 78:826-9.
6. Rieu M, Lame MQ Richard A et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol 1995 ; 42:453-60.
7. Niccoli P, Wion-Barbot N, Caron P et al. Interest of routine measurement of serum calcitonin (CT): study in a large series of thyroidectomized patients. J Clin Endocrinol Metab 1997 ; 82:338-41.
8. Modigliani E, Vasen HFA, Raue K et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. J Intern Med 1995 ; 238:363-7.
9. Vasen HFA, Van Der Feltz M, Raue F et al. Course of multiple endocrine neoplasia type 2B: a study of 18 cases. Arch Intern Med 1992 ; 152:1250-4.
10. Modigliani E, Cohen R, Campos JM et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 cases. Clin Endocrinol 1998 ; 48 (sous presse).
11. Vasen HFA, Nieuvenhuyzen Kruseman AC, Berkel H et al. Multiple endocrine neoplasia type 2: the value of screening and central registration; a study of 15 kindred in the Niederlands. Am J Med 1987 ; 83:847-52.
12. O'Riordan DS, O'Brien T, Weaver AL et al. Medullary thyroid carcinoma in multiple endocrine neoplasia type 2A and B. Surgery 1994 ; 116:1017-23.
13. Howe JR, Norton A, Wells SA. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2 A: results of long term follow-up. Surgery 1993 ; 114:1070-5.
14. Kraimps JL, Denisot A, Carnaille B et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A: a retrospective french multicentric study. World J Surg 1996 ; 20:808-13.
15. Eng C. The RET proto-oncogene in multiple endocrine neoplasia Type 2 and Hirschprung disease. N Engl J Med 1996 ; 335:943-51.
16. Schuffenecker I, Virally-Monod M, Brohet R et al. Risk and penetrance of primary hyperparathyroidism in MEN2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 1998 ; 83:487-91.
17. Moers AJ, Landsvater RM, Schaap C et al. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlations in a large family. Am J Med 1996 ; 101:635-41.
18. Takai SI, Kinoshita S, Tanaka F, Ikeda M, Tanaka N, Kobayashi T. Prominent corneal nerves in patients with multiple endocrine neoplasia type 2: diagnostic implications. World J Surg 1992 ; 16:620-3.
19. Gagel RF, Levy ML, Donovan DT et al. Multiple endocrine neoplasia type 2A associated with cutaneous lichen amyloidosis. Ann Intern Med 1989 ; 111:802-5.
20. Chabre O, Labat F, Pinel N, Berthod F, Tatel Y, Bachelot I. Cutaneous lesions associated with multiple endocrine neoplasia type 2A : lichen amyloidosis or notalgia paresthetica. Henry Ford Hosp Med J 1992 ; 40:245-8.
21. Caron Ph, Attié T, David D et al. C618R Mutation in Exon 10 of the RET Proto-Oncogene in a Kindred with Multiple Endocrine Neoplasia Type 2A and Hirschsprung's Disease. J Clin Endocrinol Metab 1996 ; 81:2731-3.
22. Eng C, Clayton D, Schuffenecker I et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 international RET mutation consortium analysis. JAMA 1996 ; 276:1575-9.
23. Casanova S, Rosenberg-Bourgin M, Farkas D C et al. Pheochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases. Clin Endocrinol 1993 ; 38:531-7.
24. Evans DB, Lee JE, Merrell RC, Hickey RC. Adrenal medullary disease in multiple endocrine neoplasia type 2; appropriate management. Endocr Metab Clin North Am 1994 ; 23:167-76.
25. Cohen R, Buchsenschutz B, Estrade P, Gardet P, Modigliani E et le GETC. Causes de mortalité chez les patients atteints de cancer médullaire. Presse Med 1996 ; 25:1819-22.
26. Vistelle R, Grulet H, Gibbol B et al. High permanent plasma adrenaline levals : a marker of adrenal medullary disease in medullary thyroid carcinoma. Clin Endocrinol 1991 ; 34:133-8.
27. Mornex R, Peyrin L Pagliani R, Cottet-Emard M. Measurement of plasma methoxyamines for the diagnosis of pheochromocytoma. Hormone Res 1991 ; 36:220-6.
28. Lender JWM, Keiser HR, Goldstein DS et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 1995 ; 123:101-5.
29. Lips CJM, Veer J, Struyenberg A et al. Bilateral occurrence of pheochromocytoma in patients with the Multiple Endocrine Neoplasia sundrome type 2A (Sipple syndrome). Am J Med 1981 ; 70:1051-60.
30. Dralle H, Shurmeyer T, Kozerke T et al. Surgical aspects of familial pheochromocytoma. Horm Metab Res 1989 ; suppl 21:34-8.
31. Lecomte-Houcke M, Duhamel A, Labat-Moleur F et al. Histomorphologic findings in pheochromocytomas associated with Multiple endocrine neoplasia type 2A 5th Intern. Workshop on MEN, Stockholm, 29 Juin-3 Juillet 1994, abstract 815, p. 102.
32. Telenius Berg M, Berg B, Hamberger B. Screening for early symptomatic pheochromocytoma in MEN 2. Henry Ford Hospital Med J 1987 ; 35:110-4.
33. Raue F, Kraimps JL, Dralle H et al. Primary hyperparathyroïdism in multiple endocrine neoplasia type 2: european study. J Intern Med 1995 ; 238:369-73.
34. Murat A, Modigliani E, Conte-Devolx B et al. Prise en charge thérapeutique précoce des sujets prédisposés génétiquement au cancer médullaire du corps thyroïde. Ann Chir 1998 (sous presse).